President and COO of CannTrust, Brad Rogers talks about the company’s standardized product lines.
The focus of CannTrust is the standardization of cannabis and delivering it to both medical and recreational channels. What’s unique and different about CannTrust is the fact that we’ve pharmaceutically standardized all of our product lines. So doctors can dose and titrate effectively. CannTrust, along with it’s unique dose forms that it’s developing for the medical channel, also owns a patent for single serve, brewing technology. So coffee, tea, hot chocolate. We’ve standardized that dosing to 10, 25 and 50 milligrams across all three. CannTrust is very judicious with it’s use of capital. We have created a 5 hundred plus million dollar market cap to date with 47 million dollars raised. So that’s one of the most effective capital uses in this industry. Management comes from scale businesses, this is not a mom and pop business so, we have the acumen to take this company far. Growing this industry (pun intended) is something that I don’t think anybody will ever see in this lifetime again. This is prohibition coming out of prohibition. CannTrust just began shipping internationally. Our first market we entered is Australia and our next markets we are going to be shipping our pharmaceutically standardized products to are Germany, Denmark and Brazil.
As a federally regulated licensed producer, we bring more than 40 years of pharmacy and healthcare experience to the Medical Cannabis industry and apply this expertise to produce standardized Medical Cannabis for patients in need as we sell 100% pesticide free product.
At CannTrust™ we are committed to research and innovation, as well as contributing to the growing body of evidence-based research regarding the use and efficacy of cannabis. Our product development teams along with our exclusive Pharma partner Apotex are diligently innovating and developing products that will make it easier for patients to use Medical Cannabis today and in the future. We support ongoing patient education about Medical Cannabis, and have launched a compassionate use program to support patients with financial needs.
Our 50,000-square foot state-of-the-art hydroponic facility provides control and results, combined with a patient-centric focus, ensures we are producing quality products and delivering superior service to our customers.
CannTrust has been granted a Section 9 License by Health Canada under the Narcotic Control Regulations. This allows us to expand our product development and research to include pharmaceuticals in an effort to better serve all Patients and Customers.
For more information on CannTrust (TRST.TSX) please fill out the form below.